The effect of intrinsic subtype on inhibition of tumor growth by anastrozole vs. fulvestrant vs. the combination: Results from the Alliance neoadjuvant endocrine therapy (NET) ALTERNATE trial.
- Citation:
- Cancer Res vol 82 (12_suppl) Abstract CT026
- Meeting Instance:
- AACR 2022
- Year:
- 2022
- Type:
- Abstract
- Sub type:
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- No
- Parents:
- None
- Children:
- None
- Pharmas:
- AstraZeneca, Genentech
- Grants:
- U10CA180821, U10CA180882, U24CA196171
- Corr. Author:
- Authors:
- Matthew J. Ellis Meenakshi Anurag Jeremy Hoog Aranzazu Fernandez-Martinez Cheng Fan Richard Gibbs Souzan Sanati Kiran Vij Travis Dockter Olwen Hahn Joseph Guenther Abigail Caudle Erika Crouch Amy Tiersten Monica Mita Wajeeha Razaq Tina J. Hieken Yang Wang A. Marilyn Leitch Gary W. Unzeitig Eric Winer Anna Weiss Kelly Hunt Ann H. Partridge Charles M. Perou Cynthia X. Ma Vera Suman Lisa A Carey
- Networks:
- CA016, KY015, LAPS-CT018, LAPS-IL057, LAPS-MA036, LAPS-MN026, LAPS-MO011, LAPS-NC007, LAPS-OK003, LAPS-TX011, LAPS-TX035, NEWMEXICO, NY021, NY167, TX041, TX190
- Study
- Alliance-A011106
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: